endometrial cancer
FDA Expands Endometrial Cancer Indication for Jemperli With Chemotherapy
The FDA has approved Jemperli, GSK with carboplatin and paclitaxel for adult patients with primary advanced or ...
AUGUST 2, 2024
FDA Approves Keytruda With Chemo for Primary Advanced or Recurrent Endometrial Carcinoma
The FDA has approved Keytruda with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult ...
JUNE 18, 2024
Combined Dostarlimab, Standard of Care Improves Survival for Endometrial Cancer Patients
Adding the PD-1 checkpoint inhibitor Jemperli to carboplatin and paclitaxel improves survival in patients with ...
MAY 13, 2023
Jemperli Gets Full Approval for Endometrial Cancer
The FDA approved Jemperli for adult patients with dMMR recurrent or advanced endometrial cancer, that has ...
FEBRUARY 15, 2023
Pembrolizumab Newly Indicated to Treat Advanced Endometrial Carcinoma
The FDA approved pembrolizumab (Keytruda, Merck) for the treatment of patients with microsatellite instability?high ...
MARCH 23, 2022
New PD-1 Jemperli Approved to Treat Mismatch Repair–Deficient Endometrial Cancer
The FDA granted accelerated approval to the programmed death receptor-1-blocking antibody dostarlimab-gxly ...
MAY 4, 2021
